

Oral Session Program

It will be held on demand. (March 12-31)

O6-9

Long-Term Follow-Up of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma (LBCL)

Caron A. Jacobson (Dana-Farber Cancer Institute, Boston, MA, USA)

O6-10

ZUMA-5 Phase 2 Study of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Caron A. Jacobson (Dana-Farber Cancer Institute, Boston, MA, USA)

O6-11

Prophylactic Steroids With Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma

Olalekan O. Oluwole (Vanderbilt-Ingram Cancer Center, Nashville, TN, USA)

O6-12

Axicabtagene Ciloleucel (Axi-Cel) in First-Line High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu (The University of Texas MD Anderson Cancer Center, Houston, TX, USA)

O6-13

Liso-cel, a Novel Anti-CD19 CAR T Cell Product, in Japanese Patients With R/R B-NHL: Phase 2 Results

Shinichi Makita¹ (National Cancer Center Hospital, Tokyo, Japan)

O8-2

Posttransplant Outcomes in Relapsed/Refractory FLT3-mutated AML Patients Treated With Gilteritinib

Yoshinobu Maeda (Okayama University Hospital, Okayama, Japan)

Poster Program

It will be held on demand. (March 12-31)

P-065

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukemia (AML)

Chikashi Yoshida (National Hospital Organization, Mito Medical Center, Ibarakimachi, Japan)

P-066

Venetoclax with azacitidine in Japanese patients with treatment-naive acute myeloid leukemia

Atsushi Shinagawa (Hitachi General Hospital, Hitachi, Ibaraki, Japan)

P-067

Real-World Treatment Patterns and Clinical Outcomes in Unfit Patients with AML in Japan

Masahiro Kizaki (Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan)

P-143

Characteristics of hepatic SOS/VOD after allo-HCT in adults in Korea

Jae-Ho Yoon (Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)